Halozyme CEO Sells $3.2M in Stock Through Planned Trading Program
Halozyme Therapeutics (HALO) President and CEO Helen Torley executed a series of pre-planned transactions under a Rule 10b5-1 trading plan established on March 21, 2025.
Rhea-AI Filing Summary
Halozyme Therapeutics (HALO) President and CEO Helen Torley executed a series of pre-planned transactions under a Rule 10b5-1 trading plan established on March 21, 2025. The transactions occurred over three consecutive days:
- June 20, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares at avg. $52.96
- June 23, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares at avg. $52.57
- June 24, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares (4,489 at avg. $53.11 and 15,511 at avg. $53.91)
Following these transactions, Torley holds 733,719 shares directly and 316,569 options at $8.11 strike price expiring February 3, 2026. The options were originally granted in 2016 with a 4-year vesting schedule. All transactions were executed under a pre-established 10b5-1 trading plan, demonstrating compliance with insider trading regulations.
Positive
- The insider transactions were executed according to a pre-planned 10b5-1 trading plan established on March 21, 2025, indicating compliance with insider trading regulations
- CEO Helen Torley still maintains a significant position of 733,719 shares after the transactions, showing continued alignment with shareholder interests
- The sales were made at favorable price points between $51.94 and $54.05, significantly higher than the $8.11 exercise price, reflecting strong stock performance
Negative
- CEO Helen Torley sold a total of 60,000 shares over three consecutive days (June 20-24, 2025), which could be perceived as a bearish signal by the market
- The exercised options were from a 2016 grant nearing expiration (Feb 2026), suggesting the sales were more timing-driven than opportunistic
- The insider's direct ownership decreased by approximately 7.5% (from 793,719 to 733,719 shares) through these transactions
Insider Trade Summary
Exercise and Sale: 60,000 shares ($2.70M approx. pre-tax spread)
Exercise and Sale
10 txns
Insider
Torley Helen
Role
PRESIDENT AND CEO
Sold
60,000 shs ($3.19M)
Approx. gross sale proceeds
$3.19M
Approx. exercise cost
$487K
Approx. pre-tax spread
$2.70M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option to Purchase Common Stock | 20,000 | $8.11 | $162K |
| Exercise | Common Stock | 20,000 | $8.11 | $162K |
| Sale | Common Stock | 4,489 | $53.109 | $238K |
| Sale | Common Stock | 15,511 | $53.911 | $836K |
| Exercise | Option to Purchase Common Stock | 20,000 | $8.11 | $162K |
| Exercise | Common Stock | 20,000 | $8.11 | $162K |
| Sale | Common Stock | 20,000 | $52.573 | $1.05M |
| Exercise | Option to Purchase Common Stock | 20,000 | $8.11 | $162K |
| Exercise | Common Stock | 20,000 | $8.11 | $162K |
| Sale | Common Stock | 20,000 | $52.96 | $1.06M |
Holdings After Transaction:
Option to Purchase Common Stock — 316,569 contracts (Direct);
Common Stock — 733,719 shares (Direct)
Footnotes (6)
- F1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1.
- F2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $52.71 to $53.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $51.94 to $52.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $52.64 to $53.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $53.65 to $54.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was the price range of HALO stock sales by CEO Helen Torley on June 24, 2025?
On June 24, 2025, CEO Helen Torley sold HALO shares in two tranches: 4,489 shares at prices ranging from $52.64 to $53.63 (weighted average $53.109) and 15,511 shares at prices ranging from $53.65 to $54.05 (weighted average $53.911).
Was HALO CEO Helen Torley's stock sale planned in advance?
Yes, the options exercises and stock sales were made pursuant to a Rule 10b5-1 written trading plan that CEO Helen Torley adopted on March 21, 2025. This type of plan allows executives to preset future trades to avoid insider trading concerns.
What is the exercise price of HALO stock options sold by CEO Helen Torley?
CEO Helen Torley exercised stock options with a strike price of $8.11 per share. These options were originally granted on February 3, 2016, with a 4-year vesting schedule of 25% after 12 months and 1/48th monthly thereafter.
AI-generated analysis. How Rhea-AI works. Not financial advice.
